Holen Sie sich die Stockscreener-App
84.70
1.77%
1.05
Schlusskurs vom Vortag:
$83.65
Offen:
$83.24
24-Stunden-Volumen:
372.87K
Relative Volume:
0.39
Marktkapitalisierung:
$6.41B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-159.39M
KGV:
-23.93
EPS:
-3.5401
Netto-Cashflow:
$-105.22M
1W Leistung:
+4.27%
1M Leistung:
+18.12%
6M Leistung:
+1,081%
1J Leistung:
+594.37%
1-Tages-Spanne:
$83.05
$85.47
1-Wochen-Bereich:
$79.95
$85.47
52-Wochen-Spanne:
$4.77
$85.47
Abivax Adr Stock (ABVX) Company Profile
Vergleichen Sie ABVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
84.84 | 6.20B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.44 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.27 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.00 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
322.25 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-12-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | Laidlaw | Buy |
| 2024-05-20 | Eingeleitet | BTIG Research | Buy |
| 2024-04-29 | Eingeleitet | Guggenheim | Buy |
| 2024-04-29 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-14 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Abivax Adr Aktie (ABVX) Neueste Nachrichten
Analysts Bullish on Healthcare Stocks: Labcorp Holdings and Abivax SA Sponsored ADR - AInvest
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 28.7% in July - Defense World
Analysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Target Price at $92.33 - Defense World
2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool
Abivax (NASDAQ:ABVX) Stock Price Up 5.2% on Analyst Upgrade - Defense World
Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax - Defense World
Lifesci Capital Brokers Lift Earnings Estimates for Abivax - Defense World
Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $78.75 - Defense World
Abivax SA Announces $608.6 Million Public Offering of ADSs - The Globe and Mail
Abivax (NASDAQ:ABVX) Reaches New 52-Week High on Analyst Upgrade - Defense World
Abivax SA Stock Surges on Promising Drug Results - TipRanks
Abivax (NASDAQ:ABVX) Trading 577.5% Higher on Analyst Upgrade - Defense World
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Abivax (NASDAQ:ABVX) Hits New 52-Week High on Analyst Upgrade - Defense World
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results - Investor's Business Daily
10 Best First Jobs for Aspiring CEOs - inkl
Prologis Inc (PLD) Stock: Navigating Drops and Gains - investchronicle.com
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod - TipRanks
Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks
Harmony Gold Mining ADR Shows Market Leadership With Jump To 82 RS Rating - inkl
Grid Metals (CVE:GRDM) Shares Up 44.4% – Here’s What Happened - Defense World
The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com
Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analyst Coverage Updates - The Globe and Mail
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease - TipRanks
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks
Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail
European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize
Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks
Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks
Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks
Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks
Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Finanzdaten der Abivax Adr-Aktie (ABVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):